Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Status:
Not yet recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate eradication rate, drug compliance, and adverse events in
patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth,
metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and
tetracycline for 14 days (LBMT)